This page shows the latest FSG news and features for those working in and with pharma, biotech and healthcare.
Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Leerink analyst Joseph Schwartz has suggested
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...